Needham raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $103 from $90 and keeps a Buy rating on the shares. The company reported “strong” Q4 results and has a “catalyst rich” 2026, the analyst tells investors in a research note. Needham sees upside to Ionis’ 2026 revenue outlook as the year progresses. It views the stock’s risk/reward as favorable into the company’s data readouts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Buy Rating Driven by Strong Q4 Beat, Growing Commercial Portfolio, and Pipeline Upside Catalysts
- Ionis Pharmaceuticals sees FY26 revenue $800M-$825M, consensus $914.39M
- Ionis Pharmaceuticals reports Q4 EPS ($1.41), consensus ($1.22)
- IONS Earnings this Week: How Will it Perform?
- Ionis Ends Early-Stage Hero Study in Down Syndrome Alzheimer’s Risk: What Investors Should Know